Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-blind Placebo-controlled Phase I Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects During Experimental Endotoxemia

Trial Profile

A Randomized Double-blind Placebo-controlled Phase I Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects During Experimental Endotoxemia

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adrecizumab (Primary)
  • Indications Septic shock
  • Focus Adverse reactions
  • Sponsors Adrenomed
  • Most Recent Events

    • 19 Dec 2018 According to an Adrenomed media release, results of the two phase I trials (NCT02991508 and NCT03083171) were presented by Dr. Jens Zimmermann (Chief Medical Officer of Adrenomed AG) at the 2nd scientific symposium (Endothelial Dysfunction-Adrenomedullin as a diagnostic and therapeutic target) which was hosted by Adrenomed AG.
    • 01 Jun 2018 Results assessing safety, tolerability and PK/PD of Adrecizumab in two randomised studies ( NCT02991508 and NCT03083171) published in the British Journal of Clinical Pharmacology
    • 25 Sep 2017 According to an Adrenomed media release, Dr Christopher Geven is lead investigator of this and other Phase I study (see profile 279742).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top